deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 20-arm NCT00262470

Treatment of Orthostatic Intolerance

Sponsor: National Center for Advancing Translational Sciences (NCATS)

Conditions Chronic Orthostatic Intolerance Tachycardia
Interventions Abdominal binder Acetazolamide Atomoxetine Atomoxetine & Propranolol Breathing Device Clonidine Drinking Water Entacapone Entacapone & Propranolol IV Saline Indomethacin Isosorbide Dinitrate Mecamylamine Melatonin Midodrine Modafinil Modafinil & Propranolol NO Drug Octreotide Placebo Propranolol Sertraline memantine
Updated 15 times since 2017 Last updated: Oct 3, 2025 Started: Apr 30, 1997 Primary completion: Dec 31, 2029 Completion: Dec 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Chronic Orthostatic Intolerance and Tachycardia and is currently ongoing. National Center for Advancing Translational Sciences (NCATS) leads this study, which shows 15 recorded versions since 1997 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Sep 2019 · 12 months · monthly snapshot~Sep 2019 – ~Oct 2020 · 13 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Nov 2025 · 12 months · monthly snapshot~Nov 2025 – present · 9 months · monthly snapshot

Change History

15 versions recorded

  1. Nov 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Nov 2024 — Nov 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Oct 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Sep 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Oct 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Sep 2019 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Sep 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Feb 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Apr 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Center for Advancing Translational Sciences (NCATS)
  • Satish R. Raj
Data source: Vanderbilt University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations